Skip to main content
Premium Trial:

Request an Annual Quote

Eli Lilly Selects Cyntellect s Technology for RNAi Studies

Note: This article has been updated to reflect a factual inaccuracy at the end of the original story, which stated that Cyntellect was a subsidiary of Oncosis.

 

NEW YORK, Nov. 4 (GenomeWeb News) - Eli Lilly has selected Cyntellect's LEAP technology for high-throughput RNA interference studies, Cyntellect said today.

 

LEAP, or Laser Enabled Analysis and Processing technology, involves a CCD camera imaging system with mirrors that steer the image in tandem with the cameras, and a laser that then works with the imaging system, according to Cyntellect, of San Diego.

 

Cyntellect has earlier said it believes this laser-driven method, which it terms optoinjection, is better than other techniques for transfecting RNAi or siRNA into cells because it more efficiently transfects cells than other methods, kills fewer cells, and allows users to transfect one cell but not the adjacent one with the RNA molecules.

 

The parties did not disclose the financial terms of the agreement.

 

Cyntellect, a spin-out of moribund stem cell cancer treatment company Oncosis, announced in July that it had received an $183,000 SBIR grant to develop its LEAP platform.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.